PMID- 30406111
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231004
IS  - 2296-889X (Print)
IS  - 2296-889X (Electronic)
IS  - 2296-889X (Linking)
VI  - 5
DP  - 2018
TI  - The Role of PI3K in Met Driven Cancer: A Recap.
PG  - 86
LID - 10.3389/fmolb.2018.00086 [doi]
LID - 86
AB  - The Receptor Tyrosine Kinase (RTK) Met, overexpressed or mutated in cancer, plays 
      a major role in cancer progression and represents an attractive target for cancer 
      therapy. However RTK inhibitors can lead to drug resistance, explaining the 
      necessity to develop therapies that target downstream signaling. 
      Phosphatidylinositide 3-kinase (PI3K) is one of the most deregulated pathways in 
      cancer and implicated in various types of cancer. PI3K signaling is also a major 
      signaling pathway downstream of RTK, including Met. PI3K major effectors include 
      Akt and "mechanistic Target of Rapamycin" (mTOR), which each play key roles in 
      numerous and various cell functions. Advancements made due to the development of 
      molecular and pharmaceutical tools now allow us to delve into the roles of each 
      independently. In this review, we summarize the current understanding we possess 
      of the activation and role of PI3K/Akt/mTOR, downstream of Met, in cancer.
FAU - Hervieu, Alexia
AU  - Hervieu A
AD  - Signal Transduction and Molecular Pharmacology Team, Cancer Therapeutics 
      Division, Institute of Cancer Research, Sutton, United Kingdom.
AD  - Spatial Signalling Team, Centre for Tumor Biology, Barts Cancer Institute, Queen 
      Mary University of London, London, United Kingdom.
FAU - Kermorgant, Stephanie
AU  - Kermorgant S
AD  - Spatial Signalling Team, Centre for Tumor Biology, Barts Cancer Institute, Queen 
      Mary University of London, London, United Kingdom.
LA  - eng
GR  - G0501003/MRC_/Medical Research Council/United Kingdom
GR  - MR/R009732/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20181024
PL  - Switzerland
TA  - Front Mol Biosci
JT  - Frontiers in molecular biosciences
JID - 101653173
PMC - PMC6207648
OTO - NOTNLM
OT  - Akt
OT  - Met
OT  - PI3K
OT  - cancer
OT  - mTOR
OT  - signaling
EDAT- 2018/11/09 06:00
MHDA- 2018/11/09 06:01
PMCR- 2018/01/01
CRDT- 2018/11/09 06:00
PHST- 2018/07/06 00:00 [received]
PHST- 2018/09/10 00:00 [accepted]
PHST- 2018/11/09 06:00 [entrez]
PHST- 2018/11/09 06:00 [pubmed]
PHST- 2018/11/09 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fmolb.2018.00086 [doi]
PST - epublish
SO  - Front Mol Biosci. 2018 Oct 24;5:86. doi: 10.3389/fmolb.2018.00086. eCollection 
      2018.